# Austin Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/austin-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 46.7 |
| Citations | 800,125 |
| City | Melbourne |
| Country | AU |
| Description | Austin Hospital is a research organisation in Melbourne, AU. OpenAlex records 10,029 works and 800,125 citations for it. 1,619 researchers list it as their most recent affiliation. |
| Homepage | http://www.austin.org.au/ |
| OpenAlex ID | https://openalex.org/I2800453128 |
| Region | Victoria |
| Researchers | 1,619 |
| ROR ID | https://ror.org/010mv7n52 |
| Type | healthcare |
| Works | 10,029 |

## University papers

Showing 12 of 23.

- [Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-i-egfr-i-mutated-advanced-nsclc/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-patients-with-advanced-or-metastatic-ntrk-fusion-positive-solid/)
- [Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-resected-i-egfr-i-mutated-nsclc/)
- [Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-as-first-line-treatment-of-i-egfr-i-mutation-positive-advanced-non/)
- [Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials](https://scholariq.org/papers/entrectinib-in-ros1-fusion-positive-non-small-cell-lung-cancer-integrated/)
- [Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease](https://scholariq.org/papers/naturally-occurring-human-urinary-peptides-for-use-in-diagnosis-of-chronic/)
- [Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial](https://scholariq.org/papers/adjuvant-osimertinib-for-resected-egfr-mutated-stage-ib-iiia-non-small-cell-lung/)
- [Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis](https://scholariq.org/papers/osimertinib-versus-platinum-pemetrexed-for-patients-with-egfr-t790m-advanced/)
- [Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides](https://scholariq.org/papers/diagnosis-and-prediction-of-ckd-progression-by-assessment-of-urinary-peptides/)
- [HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy](https://scholariq.org/papers/herthena-lung01-a-phase-ii-trial-of-patritumab-deruxtecan-her3-dxd-in-epidermal/)
- [Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer](https://scholariq.org/papers/phase-iii-keynote-789-study-of-pemetrexed-and-platinum-with-or-without/)

## University researchers

- [Kate Hamilton](https://scholariq.org/researchers/kate-hamilton/)

## University top topics

Showing 8 of 25.

- [Sepsis Diagnosis and Treatment](https://scholariq.org/topics/sepsis-diagnosis-and-treatment/)
- [Acute Kidney Injury Research](https://scholariq.org/topics/acute-kidney-injury-research/)
- [Hemodynamic Monitoring and Therapy](https://scholariq.org/topics/hemodynamic-monitoring-and-therapy/)
- [Respiratory Support and Mechanisms](https://scholariq.org/topics/respiratory-support-and-mechanisms/)
- [Trauma, Hemostasis, Coagulopathy, Resuscitation](https://scholariq.org/topics/trauma-hemostasis-coagulopathy-resuscitation/)
- [Cardiac, Anesthesia and Surgical Outcomes](https://scholariq.org/topics/cardiac-anesthesia-and-surgical-outcomes/)
- [Cardiac Arrest and Resuscitation](https://scholariq.org/topics/cardiac-arrest-and-resuscitation/)
- [Receptor Mechanisms and Signaling](https://scholariq.org/topics/receptor-mechanisms-and-signaling/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.